For drug developers, the ADVOCATE trial that enabled FDA approval of avacopan to treat ANCA-associated vasculitis reported the GTI as a critical secondary endpoint in demonstrating avacopan efficacy. For patients, an asthma cohort study determined that measuring glucocorticoid toxicity systematically with the GTI may help determine which patients would derive the most benefit from new steroid-sparing therapies